Biophytis raises €2 million in funding

Biophytis SA has announced a fundraising round of over €2 million. This capital increase was achieved through the issuance of new shares and warrants, subscribed to by institutional investors such as Alumni Capital and Hexagon Capital Fund. The transaction also allows Biophytis to fully repay its convertible debt at a variable price, with €1.025 million repaid to Atlas.

The funds raised will be used to strengthen clinical development, notably to launch a phase 3 study on sarcopenia in partnership with a joint venture in Hong Kong. Milestones are also planned for advancements in obesity, supporting regulatory activities in Brazil. With this transaction, Biophytis aims to position itself at the forefront of biotechnology applied to longevity, in the context of an aging population and increasing obesity.